MX349239B - Sistema de cest que muestran una sensibilidad independiente de la concentración. - Google Patents

Sistema de cest que muestran una sensibilidad independiente de la concentración.

Info

Publication number
MX349239B
MX349239B MX2013004825A MX2013004825A MX349239B MX 349239 B MX349239 B MX 349239B MX 2013004825 A MX2013004825 A MX 2013004825A MX 2013004825 A MX2013004825 A MX 2013004825A MX 349239 B MX349239 B MX 349239B
Authority
MX
Mexico
Prior art keywords
cest
concentration independent
systems exhibiting
nmr
responsiveness
Prior art date
Application number
MX2013004825A
Other languages
English (en)
Other versions
MX2013004825A (es
Inventor
Uggeri Fulvio
Aime Silvio
Delli Castelli Daniela
Terreno Enzo
Livio Longo Dario
Fedeli Franco
Original Assignee
Bracco Imaging Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging Spa filed Critical Bracco Imaging Spa
Publication of MX2013004825A publication Critical patent/MX2013004825A/es
Publication of MX349239B publication Critical patent/MX349239B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

La presente invención se relaciona con el uso de protones móviles no equivalentes que pertenecen a los estereoisómeros de un agente de CEST que se distinguen por NMR en un procedimiento de captura de imágenes radiométricas basadas en CEST y a los compuestos del complejo de Lantánido (III) que despliegan al menos dos estereoisómeros en solución que se distinguen por NMR útiles como agentes sensibles de CEST independientes de la concentración.
MX2013004825A 2010-11-05 2011-11-04 Sistema de cest que muestran una sensibilidad independiente de la concentración. MX349239B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190161A EP2457594A1 (en) 2010-11-05 2010-11-05 Cest systems exhibiting a concentration independent responsiveness
PCT/EP2011/069406 WO2012059576A1 (en) 2010-11-05 2011-11-04 Cest systems exhibiting a concentration independent responsiveness

Publications (2)

Publication Number Publication Date
MX2013004825A MX2013004825A (es) 2013-06-03
MX349239B true MX349239B (es) 2017-07-18

Family

ID=43530158

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004825A MX349239B (es) 2010-11-05 2011-11-04 Sistema de cest que muestran una sensibilidad independiente de la concentración.

Country Status (11)

Country Link
US (2) US10232060B2 (es)
EP (2) EP2457594A1 (es)
JP (2) JP2013542948A (es)
KR (1) KR20130138807A (es)
CN (1) CN103260652B (es)
AU (1) AU2011325112B2 (es)
CA (1) CA2816948C (es)
IL (1) IL226123A (es)
MX (1) MX349239B (es)
RU (1) RU2605823C2 (es)
WO (1) WO2012059576A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10791989B2 (en) * 2013-04-05 2020-10-06 The Trustees Of The University Of Pennsylvania Magnetic resonance imaging of poly-L-glutamate
KR101653064B1 (ko) * 2014-12-26 2016-09-09 에스티팜 주식회사 가도부트롤의 제조방법
WO2016123446A1 (en) * 2015-01-30 2016-08-04 The Johns Hopkins University Label-free mr imaging of tumor malignancy
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
SI3753929T1 (sl) * 2015-12-10 2023-01-31 Bracco Imaging Spa Dimerna kontrastna sredstva
WO2017109111A1 (en) * 2015-12-23 2017-06-29 Bracco Imaging Spa Ratiometric pulsed cest imaging
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CN108047151B (zh) * 2018-01-03 2020-08-04 广州康瑞泰药业有限公司 一种高收率钆布醇的制备方法
KR20210095168A (ko) 2018-11-23 2021-07-30 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
WO2020127154A1 (en) 2018-12-18 2020-06-25 Bracco Imaging Spa Pharmaceutical compositions comprising gd-complexes and polyarylene additives
US20200397924A1 (en) * 2019-01-28 2020-12-24 Hubei Tianshu Pharmaceutical Co., Ltd Preparation method of intermediate of gadolinium-based ionic contrast agent and use thereof
US20240036134A1 (en) * 2022-07-26 2024-02-01 Canon Medical Systems Corporation pH CALCULATING APPARATUS, MAGNETIC RESONANCE IMAGING APPARATUS, AND pH CALCULATING METHOD

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
GB9504910D0 (en) 1995-03-10 1995-04-26 Nycomed Imaging As Compounds
US6963769B1 (en) 1999-04-21 2005-11-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for enhancing contrast produced by MRI
US6875419B2 (en) * 2000-11-20 2005-04-05 Board Of Regents The University Of Texas System Paramagnetic metal ion-based macrocyclic magnetization transfer contrast agents and method of use
EP1331012A1 (en) * 2002-01-29 2003-07-30 BRACCO IMAGING S.p.A. Responsive paramagnetic MRI contrast agents
EP1466629A1 (en) * 2003-04-11 2004-10-13 BRACCO IMAGING S.p.A. Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for "CEST" applications
JP2008513533A (ja) * 2004-09-23 2008-05-01 ゲルベ Ｃｅｓｔイメージング用の造影剤封入システム
EP2035044B1 (en) * 2006-06-09 2013-10-16 Koninklijke Philips N.V. Elimination of contrast agent concentration dependency in mri
EP2229182A2 (en) * 2007-12-07 2010-09-22 Koninklijke Philips Electronics N.V. Polymeric drug carrier for image-guided delivery
EP2067485A1 (en) * 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement

Also Published As

Publication number Publication date
RU2605823C2 (ru) 2016-12-27
US10232060B2 (en) 2019-03-19
EP2635311A1 (en) 2013-09-11
RU2013125778A (ru) 2014-12-10
CA2816948C (en) 2016-04-05
MX2013004825A (es) 2013-06-03
WO2012059576A1 (en) 2012-05-10
KR20130138807A (ko) 2013-12-19
EP2457594A1 (en) 2012-05-30
CA2816948A1 (en) 2012-05-10
CN103260652A (zh) 2013-08-21
IL226123A (en) 2016-02-29
JP2017078080A (ja) 2017-04-27
CN103260652B (zh) 2016-10-12
US20130195768A1 (en) 2013-08-01
JP6542748B2 (ja) 2019-07-10
IL226123A0 (en) 2013-06-27
JP2013542948A (ja) 2013-11-28
AU2011325112A1 (en) 2013-05-02
US20190209713A1 (en) 2019-07-11
EP2635311B1 (en) 2017-08-16
AU2011325112B2 (en) 2016-03-31
US10328162B1 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
MX349239B (es) Sistema de cest que muestran una sensibilidad independiente de la concentración.
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
CY1119345T1 (el) Μακροκυκλικες ενωσεις ως αναστολεις κινασης trk
TN2017000505A1 (en) New gadolinium chelate compounds for use in magnetic resonance imaging
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
GB201004200D0 (en) Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
EP2150105A4 (en) EX-VIVO SYSTEMS AND METHODS OF CARE OF ORGANS BY USING LACTATE AS INDICATOR
BR112014017169A8 (pt) máquina de bebidas com módulo removível
ECSP14013327A (es) Compuestos con actividad nematicida
ECSP12012213A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos ? 2 y como antagonistas muscarinicos m3
EP2530093A4 (en) NOVEL INDOCYANINE COMPOUND, SYNTHESIS METHOD THEREFOR, CLEANING PROCESS THEREFOR, DIAGNOSTIC COMPOSITION WITH THE INDOCYANINE COMPOUND, DEVICE FOR MEASURING IN VIVO MOVEMENTS AND DEVICE FOR VISUALIZING CIRCULATIONS USING DIAGNOSIS COMPOSITION
MX2012007041A (es) Quelados de manganeso y su uso como agentes de contraste en elaboracion de imagen de resonancia magnetica (mri).
CR20130239A (es) Compuestos de triazolopiridina
HK1210943A1 (en) Nuclear magnetic resonance diagnostic agent, and method for detecting or diagnosing state of cell, tissue or organ in subject using same
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
NI201100176A (es) Nuevos derivados de compuestos de [3, 2-c] pirazol esteroidal con actividad glucocorticoide
TN2013000283A1 (en) Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
MX340607B (es) Moduladores de la fosfodiesterasa 10 (pde 10).
IN2014DN03197A (es)
CY1113338T1 (el) Νεα μεθοδος για συνθεση ιβαμπραδινης και αλατων προσθηκης αυτης
IT1402938B1 (it) Attrezzatura per banchi di prova dell'impianto frenante di veicoli
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
MX2014002407A (es) Plataforma de bobina de recepcion de resonancia magnetica con engranaje selectivo entre la bobina de recepcion y la superficie de la mesa del paciente.
BR112012012905A2 (pt) derivados de difenil azepina como inibidores da reabsorção de monoamina
BR112013004981A2 (pt) composição líquida

Legal Events

Date Code Title Description
FG Grant or registration